Related Experiment Video
Updated: Jul 15, 2026
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Dual effect of AMD3100, a CXCR4 antagonist, on bleomycin-induced lung inflammation
Masaki Watanabe1, Wataru Matsuyama, Yuko Shirahama
1Division of Respiratory Medicine, Respiratory and Stress Care Center, Kagoshima University Hospital, Sakuragaoka 8-35-1, Kagoshima 890-8520, Japan.
Abstract:
The chemokine receptor CXCR4, which binds the chemokine stromal cell-derived factor 1, has been reported to be involved in the chemotaxis of inflammatory cells. In addition, AMD3100, an antagonist of CXCR4, has been reported to be an attractive drug candidate for therapeutic intervention in several disorders in which CXCR4 is critically involved. However, little is known about the therapeutic value of AMD3100 in the treatment of pulmonary fibrosis. In this study, we examined the effects of AMD3100 on a murine bleomycin-induced pulmonary fibrosis model. Concurrent administration of AMD3100 and bleomycin apparently attenuated bleomycin-induced pulmonary inflammation. In this process, an inhibition of neutrophil recruitment at early stage followed by the decrease of other inflammatory cell recruitment in the lung were observed. In addition, it also inhibited the expression of cytokines, including MCP-1, MIP-2, MIP-1alpha, and TGF-beta. In contrast, when AMD3100 was administered following bleomycin treatment, the bleomycin-induced lung inflammation progressed and resulted in severe pulmonary fibrosis. In this process, an increase of inflammatory cell recruitment, an up-regulation of lung MCP-1 and TGF-beta, and a remarkable activation of p44/42 MAPK in neutrophils were observed. U0126, an inhibitor of p44/42 MAPK, significantly abolished these effects. Thus, AMD3100 has dual effect on bleomycin-induced pulmonary fibrosis. Difference of inflammatory cell recruitment and activation might be associated with the dual effect of AMD3100 on bleomycin-induced pulmonary fibrosis.
Insights
AMD3100, a CXCR4 antagonist, shows dual effects on pulmonary fibrosis. Early administration attenuates inflammation, while late administration exacerbates it, impacting inflammatory cell recruitment and cytokine expression.
Area of Science:
- Immunology
- Pulmonary Medicine
- Pharmacology
Background:
- Chemokine receptor CXCR4 (CXCR4) and its ligand stromal cell-derived factor 1 (SDF-1) mediate inflammatory cell chemotaxis.
- AMD3100, a CXCR4 antagonist, is a potential therapeutic agent for CXCR4-related disorders.
- The therapeutic role of AMD3100 in pulmonary fibrosis remains largely unexplored.
Purpose of the Study:
- To investigate the therapeutic potential of AMD3100 in a murine model of bleomycin-induced pulmonary fibrosis.
- To elucidate the mechanisms underlying AMD3100's effects on lung inflammation and fibrosis progression.
Main Methods:
- Establishment of a bleomycin-induced pulmonary fibrosis model in mice.
- Administration of AMD3100 concurrently with or after bleomycin treatment.
- Assessment of inflammatory cell infiltration, cytokine expression (MCP-1, MIP-2, MIP-1alpha, TGF-beta), and p44/42 MAPK activation.
- Use of U0126, a p44/42 MAPK inhibitor, to confirm pathway involvement.
Main Results:
- Concurrent AMD3100 and bleomycin treatment attenuated lung inflammation by inhibiting neutrophil and other inflammatory cell recruitment.
- This early AMD3100 administration also reduced the expression of key pro-inflammatory cytokines.
- Conversely, post-bleomycin AMD3100 administration exacerbated pulmonary fibrosis, increasing inflammatory cell infiltration, cytokine levels, and p44/42 MAPK activation in neutrophils.
- Inhibition of p44/42 MAPK with U0126 reversed the detrimental effects of late AMD3100 administration.
Conclusions:
- AMD3100 exhibits a dual effect on bleomycin-induced pulmonary fibrosis, dependent on the timing of administration.
- Early intervention with AMD3100 demonstrates anti-inflammatory and protective effects.
- Late intervention exacerbates fibrosis, potentially through modulation of inflammatory cell recruitment and p44/42 MAPK signaling pathways.
